A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
This phase III clinical trial is studying how well giving tamoxifen citrate, anastrozole,
letrozole, or exemestane with or without chemotherapy works in treating patients with
invasive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone
therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by
the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may
fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in
chemotherapy work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. It is not yet known whether giving tamoxifen
citrate, anastrozole, letrozole, or exemestane is more effective with combination
chemotherapy in treating patients with breast cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.